@article{58d322d9739a4e789950157c85383413,
title = "Assessment of Early Tumour Shrinkage: Ready for Integration in the Treatment Strategy for Metastatic Renal Cell Carcinoma?",
author = "Laurence Albiges and Bernard Escudier",
note = "Funding Information: Laurence Albiges has received consulting/advisory fees from Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and research funding from Pfizer and Novartis. Bernard Escudier has received consulting/advisory fees from Bayer, Pfizer, Novartis, and Bristol-Myers Squibb; and honoraria from Bayer, Roche, Pfizer, Genentech, Novartis, AVEO Pharmaceuticals, and GlaxoSmithKline. ",
year = "2016",
month = dec,
day = "1",
doi = "10.1016/j.eururo.2016.07.050",
language = "English",
volume = "70",
pages = "1016--1018",
journal = "European Urology",
issn = "0302-2838",
number = "6",
}